REG-PanGenomic Health Inc: PanGenomic Health Provides Update for NARA Product and Conversational AI

Pangenomic HealthAnnouncement

06/06/2023 12:30

6 June 2023

 

PanGenomic Health Inc.

(“PanGenomic” or the “Company”)

PanGenomic Health Provides Update for NARA Product and Conversational AI

 

Vancouver, British Columbia, Canada, 6 June 2023 – PanGenomic Health Inc.
("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to
provide an update on its NARA product and announce that it is planning to
launch conversational AI for the NARA app and web platform ("Conversational
AI").

 

The Company released a new version of its NARA app this quarter with an
updated plant library, plant rating system, expanded video content and new
personalisation tools for women’s health. The product changes were designed
to allow users to access expanded information about natural solutions and
scientifically backed tools in their pursuit of mental and physical
well-being. With the integration of Conversational AI, users will be able to
interact with the NARA app and web platform in a more intuitive and effortless
manner through natural language dialogue.

 

"The introduction of Conversational AI is a significant stride towards
enhancing the user experience", stated Maryam Marissen, CEO of PanGenomic
Health. "We believe that Conversational AI will be a vital component in
allowing a user to take their wellness journey to new heights and further
personalise their health experience."

 

The NARA app and web platform leverage personalised data to offer tailored
insights and evidence-based solutions, and equip individuals with
comprehensive guidance backed by the latest scientific research in natural
solutions. Conversational AI will engage with the user to explore relevant
information from various sources, such as DNA profiles, existing health
regimens, self-reported feedback, and long-term wellness goals.

 

Marissen further commented, "PanGenomic Health remains committed to providing
our users with an informative, engaging and interactive experience. The
addition of Conversational AI marks an important milestone in our journey to
build future-forward products."

 

The Company is planning to launch Conversational AI on the web based NARA
platform by Q3, followed by a roll out on the NARA app by Q4 of this year.

 

For more product information, please visit nara.care or download the NARA App
at:

 

Apple App Store: www.apps.apple.com/us/app/care-with-nara/id1614523255

Google Play Store:
www.play.google.com/store/apps/details?id=com.pgxmobileclient

 

 

About PanGenomic Health

 

PanGenomic Health is a precision health company that has developed a self-care
digital platform to deliver personalised, evidence-based information about
natural treatments. The Company’s initial focus is to support mental health.
Registered as a British Columbia benefit company, PanGenomic Health's mission
is to promote and improve the health and wellness of people and society by
providing a technology platform that identifies plant-based solutions tailored
to the health profile of each individual.

 

 

 

The Directors of PanGenomic take responsibility for this announcement.

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

 

For more information, please contact:

 

Jerry Lai, Investor Relations    Maryam Marissen, President & CEO

PanGenomic Health Inc.    PanGenomic Health Inc.

778 743 4642      778 743 4642

ir@pangenomic.com     info@pangenomic.com

 

 

Novum Securities Limited, AQSE corporate Advisor

David Coffman / George Duxberry

Tel: +44 (0)207 399 9400

 

Yellow Jersey PR
Charles Goodwin / Shiv Thambirajah / Soraya Jackson
Investor Relations, UK
Tel: +44 (0)20 3004 9512

 

This news release includes certain statements that may be deemed
“forward-looking statements”, including statements respecting the services
to be provided by PanGenomic Health and the consideration to be paid to
PanGenomic Health. The use of any of the words “anticipate”,
“continue”, “estimate”, “expect”, “may”, “will”,
“would”, “project”, “should”, “believe” and similar
expressions are intended to identify forward looking statements. Although
PanGenomic Health believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance should not
be placed on the forward-looking statements because PanGenomic Health can give
no assurance that they will prove to be correct. There can be no assurance
that the proposed licensing transaction with Interactive Health Inc. will be
completed as proposed or at all. Since forward-looking statements address
future events and conditions, by their very nature they involve inherent risks
and uncertainties. These statements speak only as of the date of this News
Release. Actual results could differ materially from those currently
anticipated due to a number of factors and risks including various risk
factors discussed in PanGenomic Health’s disclosure documents which can be
found under PanGenomic Health’s profile on www.sedar.com.

 

 



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved